Caris Life Sciences announced a strategic research partnership with Incyte to augment precision medicine approaches for Incyte’s oncology pipeline. Caris’ unique platform combines data from whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures to improve patient outcomes through advancement of personalized medicine. The partnership will apply Caris’ data and analytics tools, comprehensive molecular tissue and liquid profiling services, and clinical trial enrollment program capabilities across two therapeutic programs initially, with the option for Incyte to expand to four total programs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INCY:
